Immune checkpoint inhibitors (ICI) were developed to counter the upregulation of immune checkpoints by tumors by targeting programmed cell death protein (PD‐1)/programmed death‐ligand 1 (PDL‐1) or common T lymphocyte antigen‐4 (CTLA‐4), resulting in recognition and killing of tumor cells by the host immune system. Here, CD274 is linked to neoplasm.